1358.HK
PW Medtech makes and sells high-end infusion devices, intravenous indwelling needle products and insulin needles, mostly for use in hospitals.

The Latest: Medical device maker PW Medtech Group Ltd. (1358.HK) reported Tuesday it repurchased 700,000 and 590,000 of its shares on Sept. 2 and Sept. 3, respectively.

Looking Up: The company made the purchases three days after announcing its latest financial results, suggesting management may be optimistic about its outlook, or believe that the shares are currently undervalued.

Take Note: The use of internal funds to repurchase shares may reduce the company’s cash for daily operations and future investments. In addition, the modest amount of the buyback will have a limited effect on the company’s share price.

Digging Deeper: PW Medtech makes and sells high-end infusion devices, intravenous indwelling needle products and insulin needles, mostly for use in hospitals. The company’s revenue took a hit during the pandemic, but its business has largely returned to normal over the past two years as the government promotes domestic production of medical devices. Last week it reported its revenue rose 6.1% to 338 million yuan ($47.5 million) in the first half of the year, while its adjusted profit increased 3.4% to 100 million yuan. The latest growth was slower than last year due to a government anti-corruption crackdown in the medical device sector, and an acceleration of industry consolidation.

Market Reaction: PW Medtech shares rose on Wednesday and closed up 1.8% at HK$1.11 by the midday break, near the upper end of their 52-week range.

Translation by A. Au

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Geneplus IPO

Geneplus locks onto targeted medicine for IPO pitch

After a post-Covid earnings dip, the company is seeking a stable future as a provider of data and diagnostics for precision medicine and disease prevention   Key Takeaways: The company’s…

Hong Kong’s IPO rally under scrutiny, as ZTE hits new U.S. headwinds

Hong Kong's stock regulator has warned IPO underwriters over the declining qualiy of new listing applications. Is this a red flag for the city's booming IPO market, or just the usual regulatory caution? And the U.S. could fine telecoms equipment maker ZTE $1 billion for bribery in Brazil. Why does Washington think it can force ZTE to pay such a large amount?